-
Mashup Score: 8Dual antigen targeting immunotherapies in MM - 4 day(s) ago
Here we summarize a presentation by Sham Mailankody from the International Myeloma Society’s 5th Immune Effector Cell Therapies in Multiple Myeloma Workshop, 2024, on the dual antigen-targeting CAR T cells and trispecific antibodies in MM.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Here, we summarize a subanalysis by Oriol et al. published in Clinical Lymphoma, Myeloma and Leukemia on the results of the OPTIMISMM trial by frailty status and bortezomib dose adjustment.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
Here, we summarize a publication by Murugappan, et al. in Journal of Geriatric Oncology on a comparison between approaches to measuring frailty: the patient-reported frailty phenotype (PRFP) and the International Myeloma Working Group Frailty Index (IMWG FI).
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Factors associated with unsustained MRD-negativity in patients with MM eligible for transplant - 2 month(s) ago
Here, we summarize a report published by Guerrero et al. in Blood on predictors of unsustainable MRD-negativity in patients with multiple myeloma who are eligible for transplant.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
The supplemental Biologics License Application for Abecma in this indication remains under review with the FDA; Abecma has been approved in Japan and Switzerland and received a positive CHMP Opinion by the European Medicines Agency based on KarMMa-3 Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma based on results from the pivotal Phase 3 KarMMa-3 study, including the key secondary endpoint of overall survival. The recommendation from the ODAC will be considered by the FDA during its ongoing review of the supplemental Biologics License Application (sBLA) for Abecma for this patient population. The FDA has not yet assigned a new target action date for review of the sBLA. “We
Source: news.bms.comCategories: General Medicine News, Onc News and JournalsTweet-
🚨 NEWS 🚨 @US_FDA Oncologic Drugs Advisory Committee vote in favor of ide-cel, a BCMA-directed CAR T-cell therapy, for the treatment of triple-class exposed relapsed/refractory #MultipleMyeloma; based on data from KarMMa-3. Read more: https://t.co/wKEZ0UlGLP #mmsm #myeloma… https://t.co/j8Vw4QqBg8 https://t.co/A1v5HlJ0k5
-
-
Mashup Score: 0EloPd for the treatment of RRMM: Real-world efficacy and safety data - 2 month(s) ago
Here, we summarize a publication by Gentile et al. on real-world experiences and outcomes in patients with RRMM treated with EloPd compared with clinical trial data from ELOQUENT-3.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 15VTE prophylaxis: Real-world practices and IFM clinical guidelines - 3 month(s) ago
Here, we summarize the results of a clinician survey on the real-life practices for thromboprophylaxis in multiple myeloma as well as the IFM clinical guidelines for VTE thromboprophylaxis.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Visual abstract | Autologous stem cell transplantation in newly diagnosed multiple myeloma: Real-world results - 4 month(s) ago
The Multiple Myeloma Hub is pleased to present a visual abstract on a real-world retrospective cohort study by Côté et al.1 evaluating the outcomes of ASCT performed as first-line therapy in patients with multiple myeloma.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet-
📊 There are many different treatment approaches for patients with newly diagnosed #MultipleMyeloma. Take a look at this visual abstract on a real-world retrospective study, which highlights the outcomes of patients eligible for transplant. https://t.co/6RsTFR6eiu #mmsm #myeloma https://t.co/mODDAlfGQy
-
-
Mashup Score: 5Maintenance therapy in MM: Continuing therapy vs discontinuation according to MRD status - 5 month(s) ago
Here, we summarize key points on the intensification of maintenance therapy in patients with multiple myeloma and the impact of MRD status on length of time on therapy.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Visual abstract | Autologous stem cell transplantation in newly diagnosed multiple myeloma: Real-world results - 6 month(s) ago
The Multiple Myeloma Hub is pleased to present a visual abstract on a real-world retrospective cohort study by Côté et al.1 evaluating the outcomes of ASCT performed as first-line therapy in patients with multiple myeloma.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet-
📊 There are many different treatment approaches for patients with newly diagnosed #MultipleMyeloma. Take a look at this visual abstract on a real-world retrospective study, which highlights the outcomes of patients eligible for transplant. https://t.co/6RsTFR6eiu #mmsm #myeloma https://t.co/mODDAlfGQy
-
Could dual antigen targeting help overcome resistance mechanisms to immune therapies in #MultipleMyeloma? Read our latest article to learn the rationale and preclinical evidence! https://t.co/DqS7FgNWa4 #mmsm #myeloma https://t.co/i9zD0twJGo